NO960239L - Kondenserte indanderivater og farmasöytisk akseptable salter derav - Google Patents

Kondenserte indanderivater og farmasöytisk akseptable salter derav

Info

Publication number
NO960239L
NO960239L NO960239A NO960239A NO960239L NO 960239 L NO960239 L NO 960239L NO 960239 A NO960239 A NO 960239A NO 960239 A NO960239 A NO 960239A NO 960239 L NO960239 L NO 960239L
Authority
NO
Norway
Prior art keywords
group
substituted
optionally substituted
ring
nitrogenous heterocyclic
Prior art date
Application number
NO960239A
Other languages
English (en)
Other versions
NO305555B1 (no
NO960239D0 (no
Inventor
Shinji Okazaki
Tetsuji Asao
Motoji Wakida
Keisuke Ishida
Masato Washinosu
Teruhiro Utsugi
Yuji Yamada
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of NO960239D0 publication Critical patent/NO960239D0/no
Publication of NO960239L publication Critical patent/NO960239L/no
Publication of NO305555B1 publication Critical patent/NO305555B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/18—Ring systems of four or more rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO960239A 1994-05-20 1996-01-19 Kondenserte indan-derivater og farmas°ytisk akseptable salter derav, preparat og anti-tumormiddel NO305555B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP10719094 1994-05-20
PCT/JP1995/000944 WO1995032187A1 (en) 1994-05-20 1995-05-18 Novel fused indan derivative and pharmaceutically acceptable salt thereof

Publications (3)

Publication Number Publication Date
NO960239D0 NO960239D0 (no) 1996-01-19
NO960239L true NO960239L (no) 1996-03-18
NO305555B1 NO305555B1 (no) 1999-06-21

Family

ID=14452758

Family Applications (1)

Application Number Title Priority Date Filing Date
NO960239A NO305555B1 (no) 1994-05-20 1996-01-19 Kondenserte indan-derivater og farmas°ytisk akseptable salter derav, preparat og anti-tumormiddel

Country Status (21)

Country Link
US (3) US5733918A (no)
EP (1) EP0713870B1 (no)
KR (1) KR100190732B1 (no)
CN (1) CN1131216C (no)
AT (1) ATE203236T1 (no)
AU (1) AU685631B2 (no)
CA (1) CA2167382C (no)
DE (1) DE69521770T2 (no)
DK (1) DK0713870T3 (no)
ES (1) ES2158109T3 (no)
FI (1) FI111721B (no)
GR (1) GR3036795T3 (no)
HU (1) HU218308B (no)
IL (1) IL113778A (no)
NO (1) NO305555B1 (no)
NZ (1) NZ285448A (no)
PT (1) PT713870E (no)
RU (1) RU2124017C1 (no)
TW (1) TW440562B (no)
WO (1) WO1995032187A1 (no)
ZA (1) ZA954077B (no)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3141148B2 (ja) * 1995-08-08 2001-03-05 大鵬薬品工業株式会社 縮合インダン誘導体及びその塩
DE19538088A1 (de) * 1995-10-13 1997-04-17 Bernd Prof Dr Clement Phenanthridinderivate und ihre Herstellung
US6956035B2 (en) * 2001-08-31 2005-10-18 Inotek Pharmaceuticals Corporation Isoquinoline derivatives and methods of use thereof
US20030096833A1 (en) * 2001-08-31 2003-05-22 Jagtap Prakash G. Substituted ideno[1,2-c]isoquinoline derivatives and methods of use thereof
CN1284781C (zh) * 2001-10-05 2006-11-15 霍夫曼-拉罗奇有限公司 具有抗肿瘤活性的多环化合物
US6946472B2 (en) 2002-04-30 2005-09-20 Hoffman-La Roche Inc. Polycyclic compounds exhibiting anti-tumor activities
CL2004000366A1 (es) * 2003-02-26 2005-01-07 Pharmacia Corp Sa Organizada B USO DE UNA COMBINACION DE UN COMPUESTO DERIVADO DE PIRAZOL INHIBIDOR DE QUINASA p38, Y UN INHIBIDOR DE ACE PARA TRATAR DISFUNCION RENAL, ENFERMEDAD CARDIOVASCULAR Y VASCULAR, RETINOPATIA, NEUROPATIA, EDEMA, DISFUNCION ENDOTELIAL O INSULINOPATIA.
CN100398519C (zh) * 2003-02-28 2008-07-02 伊诺泰克制药公司 四环苯甲酰胺衍生物及其用法
BRPI0508052A (pt) * 2004-02-26 2007-07-17 Inotek Pharmaceuticals Corp derivados de lactamo tetracìclico e seus usos
CA2557547A1 (en) * 2004-02-26 2005-09-09 Inotek Pharmaceuticals Corporation Isoquinoline derivatives and methods of use thereof
US20060019980A1 (en) * 2004-06-16 2006-01-26 Inotek Pharmaceutical, Corp. Methods for treating or preventing erectile dysfunction or urinary incontinence
JP2008531590A (ja) * 2005-02-24 2008-08-14 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ カリウムイオンチャンネル開口薬としての新規なキノリン誘導体
WO2006093666A2 (en) * 2005-02-25 2006-09-08 Inotek Pharmaceuticals Corporation Isoqunoline compounds and methods of use thereof
RU2007135362A (ru) * 2005-02-25 2009-03-27 Инотек Фармасьютикалз Корпорейшн (Us) Тетрациклические амино- и карбоксамидосоединения и способ их применения
WO2006093677A1 (en) * 2005-02-25 2006-09-08 Inotek Pharmaceuticals Corporation Tetracyclic sulfonamide compounds and methods of use thereof
CN101316592A (zh) * 2005-08-24 2008-12-03 伊诺泰克制药公司 茚并异喹啉酮类似物及其用法
MX2009009183A (es) * 2007-02-28 2009-09-07 Inotek Pharmaceuticals Corp Analogos de indenoisoquinolinona y metodos de utilizacion de los mismos.
CN103102304B (zh) * 2013-01-19 2015-03-11 安徽师范大学 N-磺酰基取代四氢异喹啉衍生物的制备方法
TWI603971B (zh) * 2013-08-22 2017-11-01 Taiho Pharmaceutical Co Ltd Novel quinoline substituted compounds
AU2017350440B2 (en) 2016-10-31 2023-01-12 Taiho Pharmaceutical Co., Ltd. Selective inhibitor of exon 20 insertion mutant EGFR
FI3677266T3 (fi) 2017-09-01 2024-03-22 Taiho Pharmaceutical Co Ltd Eksoni 18- ja/tai eksoni 21 -egfr-mutantille selektiivinen inhibiittori
EP4086290A1 (en) * 2021-05-04 2022-11-09 SHPP Global Technologies B.V. Capped bisphenol polyindane oligomer and composition, method of manufacture, and articles made therefrom

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60169482A (ja) * 1984-02-14 1985-09-02 Mitsubishi Chem Ind Ltd アミノ化フタライド−イソキノリン類の製法
JPH0633263B2 (ja) * 1985-05-27 1994-05-02 鐘淵化学工業株式会社 ７−ヒドロキシグアニン誘導体及びその製造方法並びにそれを有効成分とする抗腫瘍剤
SU1574598A1 (ru) * 1987-11-03 1990-06-30 Институт Химической Кинетики И Горения Со Ан Ссср Способ получени 4-диалкиламино-2-алкил(или фенил)нафто[2,3- @ ]хинолин-7,12-дионов
US5223506A (en) * 1991-06-04 1993-06-29 Glaxo Inc. Cyclic antitumor compounds

Also Published As

Publication number Publication date
KR960703864A (ko) 1996-08-31
FI960280A0 (fi) 1996-01-19
HUT75651A (en) 1997-05-28
TW440562B (en) 2001-06-16
IL113778A0 (en) 1995-08-31
DE69521770T2 (de) 2002-05-23
CN1130903A (zh) 1996-09-11
US5710162A (en) 1998-01-20
AU2454295A (en) 1995-12-18
FI111721B (fi) 2003-09-15
NO305555B1 (no) 1999-06-21
ES2158109T3 (es) 2001-09-01
ZA954077B (en) 1996-01-19
US6028079A (en) 2000-02-22
EP0713870A1 (en) 1996-05-29
NO960239D0 (no) 1996-01-19
US5733918A (en) 1998-03-31
ATE203236T1 (de) 2001-08-15
IL113778A (en) 1999-09-22
DE69521770D1 (de) 2001-08-23
WO1995032187A1 (en) 1995-11-30
KR100190732B1 (ko) 1999-06-01
CA2167382C (en) 1999-08-31
HU218308B (en) 2000-07-28
EP0713870B1 (en) 2001-07-18
AU685631B2 (en) 1998-01-22
CN1131216C (zh) 2003-12-17
CA2167382A1 (en) 1995-11-30
FI960280A7 (fi) 1996-03-18
RU2124017C1 (ru) 1998-12-27
NZ285448A (en) 1997-11-24
DK0713870T3 (da) 2001-09-24
EP0713870A4 (en) 1996-12-18
PT713870E (pt) 2001-11-30
GR3036795T3 (en) 2002-01-31

Similar Documents

Publication Publication Date Title
NO960239D0 (no) Kondenserte indanderivater og farmasöytisk akseptable salter derav
DK1178967T3 (da) Quinolinderivater som inhibitorer af MEK-enzymer
FI956270A0 (fi) Piperdiinijohdannaisia ja menetelmä niiden valmistamiseksi
FI953968A0 (fi) Antraniiliset happojohdannaiset
ATE172201T1 (de) Morphinan-derivate und medizinische verwendung
ATE339409T1 (de) Trizyklische verbindungen
DE68920796D1 (de) Chinolinderivate, ihre Herstellung und Verwendung.
ATE205199T1 (de) Quinolin- oder quinazolinderivate, deren herstellung und verwendung
DE68906183D1 (de) 2'-desoxy-5-fluoruridinderivate.
IL95839A0 (en) Quinoline derivatives,their production and use
DE69311165D1 (de) Kondensierte heterocyclische Ketonderivate, ihre Herstellung und ihre Verwendung
AU6366386A (en) 3-vinyl- and 3- ethinyl-beta-carboline derivatives their production and their use as drugs
AU6158486A (en) Dihydro pyridine derivatives
KR950704333A (ko) 신규한 세펨 유도체(novel cephem derivatives)
EP0773214A4 (en) TRIFLUORMETHYLQUINOLINE CARBONIC ACID DERIVATIVES
DE69624459D1 (de) Kondensierte indan-derivate und ihre salze
DE69634004D1 (de) Verknüpfte polycyclische heterocyclische verbindungen
DK0466662T3 (da) 6,7-Disubstituerede-2-aminotetraliner, der er aktive som immunmodulatorer, samt farmaceutiske præparater indeholdende sådanne forbindelser
CA2202031A1 (en) Condensed indan derivatives and salts thereof
PL342826A1 (en) Derivatives of cycloalkenes, their production and application